Endocrine-Related Cancer
@endocancer.bsky.social
Publishing translational & clinical investigations of human health & disease focusing on #endocrine neoplasias & hormone-dependent #cancers. Owned by Society of Endocrinology.
🚀 The new year marks an exciting transition for Endocrine-Related Cancer as Prof. Karel Pacak begins his term as Editor-in-Chief!
In a new editorial, Prof. Pacak outlines 5 principles that will guide the journal as a platform for collaboration, inspiration & progress: doi.org/10.1530/ERC-25-0497
In a new editorial, Prof. Pacak outlines 5 principles that will guide the journal as a platform for collaboration, inspiration & progress: doi.org/10.1530/ERC-25-0497
January 15, 2026 at 2:42 PM
🚀 The new year marks an exciting transition for Endocrine-Related Cancer as Prof. Karel Pacak begins his term as Editor-in-Chief!
In a new editorial, Prof. Pacak outlines 5 principles that will guide the journal as a platform for collaboration, inspiration & progress: doi.org/10.1530/ERC-25-0497
In a new editorial, Prof. Pacak outlines 5 principles that will guide the journal as a platform for collaboration, inspiration & progress: doi.org/10.1530/ERC-25-0497
A new review by Hans V. Westerhoff explores how complexity, plasticity and circular causality make intracellular networks resemble trained neural networks. Comparing disease challenges with those in evolution or development may reveal 'learned' cellular responses.
🔗 doi.org/10.1530/ERC-25-0183
🔗 doi.org/10.1530/ERC-25-0183
January 12, 2026 at 12:01 PM
A new review by Hans V. Westerhoff explores how complexity, plasticity and circular causality make intracellular networks resemble trained neural networks. Comparing disease challenges with those in evolution or development may reveal 'learned' cellular responses.
🔗 doi.org/10.1530/ERC-25-0183
🔗 doi.org/10.1530/ERC-25-0183
We are delighted to welcome Professor Ilan Shimon, MD, as a new Associate Editor for Endocrine‑Related Cancer.
A leading clinical academic endocrinologist and former ENEA President, he brings extensive expertise in pituitary tumour research.
🔗 erc.bioscientifica.com
A leading clinical academic endocrinologist and former ENEA President, he brings extensive expertise in pituitary tumour research.
🔗 erc.bioscientifica.com
January 5, 2026 at 2:15 PM
We are delighted to welcome Professor Ilan Shimon, MD, as a new Associate Editor for Endocrine‑Related Cancer.
A leading clinical academic endocrinologist and former ENEA President, he brings extensive expertise in pituitary tumour research.
🔗 erc.bioscientifica.com
A leading clinical academic endocrinologist and former ENEA President, he brings extensive expertise in pituitary tumour research.
🔗 erc.bioscientifica.com
📊 Real-world survival outcomes in neuroendocrine neoplasms (NENs)
A retrospective study by Marta Laganà et al. analysed 239 patients with NENs (2010–2023), reporting overall survival (OS), progression-free survival (PFS), and key predictors.
Read the article: doi.org/10.1530/ERC-25-0243
A retrospective study by Marta Laganà et al. analysed 239 patients with NENs (2010–2023), reporting overall survival (OS), progression-free survival (PFS), and key predictors.
Read the article: doi.org/10.1530/ERC-25-0243
December 16, 2025 at 11:02 AM
📊 Real-world survival outcomes in neuroendocrine neoplasms (NENs)
A retrospective study by Marta Laganà et al. analysed 239 patients with NENs (2010–2023), reporting overall survival (OS), progression-free survival (PFS), and key predictors.
Read the article: doi.org/10.1530/ERC-25-0243
A retrospective study by Marta Laganà et al. analysed 239 patients with NENs (2010–2023), reporting overall survival (OS), progression-free survival (PFS), and key predictors.
Read the article: doi.org/10.1530/ERC-25-0243
New research by Soumen Bera et al. supports a model where GLP1R agonism blocks oncogenic pathways and growth of prostate cancer cells, pointing to potential therapeutic applications of semaglutide in advanced prostate cancer.
👉 Read the article: doi.org/10.1530/ERC-25-0185
👉 Read the article: doi.org/10.1530/ERC-25-0185
December 8, 2025 at 2:32 PM
New research by Soumen Bera et al. supports a model where GLP1R agonism blocks oncogenic pathways and growth of prostate cancer cells, pointing to potential therapeutic applications of semaglutide in advanced prostate cancer.
👉 Read the article: doi.org/10.1530/ERC-25-0185
👉 Read the article: doi.org/10.1530/ERC-25-0185
⭐ Which articles are shaping the conversation in endocrine oncology?
Our incoming Editor‑in‑Chief, Professor Karel Pacak, has curated his first Editors’ Choice Collection.
📚 Explore the collection: erc.bioscientifica.com/page/edchoice/editors-choice
Our incoming Editor‑in‑Chief, Professor Karel Pacak, has curated his first Editors’ Choice Collection.
📚 Explore the collection: erc.bioscientifica.com/page/edchoice/editors-choice
December 2, 2025 at 2:51 PM
⭐ Which articles are shaping the conversation in endocrine oncology?
Our incoming Editor‑in‑Chief, Professor Karel Pacak, has curated his first Editors’ Choice Collection.
📚 Explore the collection: erc.bioscientifica.com/page/edchoice/editors-choice
Our incoming Editor‑in‑Chief, Professor Karel Pacak, has curated his first Editors’ Choice Collection.
📚 Explore the collection: erc.bioscientifica.com/page/edchoice/editors-choice
A new narrative review by Michaela Kuhlen, Marina Kunstreich and Antje Redlich explores how paediatric and adult DTC differ across biology, presentation, treatment strategies and guidelines, highlighting the need for harmonised, age‑specific approaches.
doi.org/10.1530/ERC-25-0191
doi.org/10.1530/ERC-25-0191
November 24, 2025 at 4:41 PM
A new narrative review by Michaela Kuhlen, Marina Kunstreich and Antje Redlich explores how paediatric and adult DTC differ across biology, presentation, treatment strategies and guidelines, highlighting the need for harmonised, age‑specific approaches.
doi.org/10.1530/ERC-25-0191
doi.org/10.1530/ERC-25-0191
Spotlighting our latest completed collections & our open collections for submissions.
✅ 𝗖𝗼𝗺𝗽𝗹𝗲𝘁𝗲𝗱 𝗖𝗼𝗹𝗹𝗲𝗰𝘁𝗶𝗼𝗻𝘀:
🔎 𝙍𝙀𝙏@𝙏𝙝𝙞𝙧𝙩𝙮 - bit.ly/4p9qspY
🔬 𝙏𝙝𝙚 𝙒𝙖𝙧𝙗𝙪𝙧𝙜 𝙀𝙛𝙛𝙚𝙘𝙩 - bit.ly/4rb6eOs
💡 𝗢𝗽𝗲𝗻 𝗳𝗼𝗿 𝗦𝘂𝗯𝗺𝗶𝘀𝘀𝗶𝗼𝗻𝘀:
🌱 𝙃𝙚𝙧𝙞𝙩𝙖𝙗𝙡𝙚 𝙀𝙣𝙙𝙤𝙘𝙧𝙞𝙣𝙚 𝘾𝙖𝙣𝙘𝙚𝙧𝙨 - bit.ly/43A22O7
🧠 𝙋𝙞𝙩𝙪𝙞𝙩𝙖𝙧𝙮 𝙏𝙪𝙢𝙤𝙪𝙧𝙨 - bit.ly/4p9qTk6
✅ 𝗖𝗼𝗺𝗽𝗹𝗲𝘁𝗲𝗱 𝗖𝗼𝗹𝗹𝗲𝗰𝘁𝗶𝗼𝗻𝘀:
🔎 𝙍𝙀𝙏@𝙏𝙝𝙞𝙧𝙩𝙮 - bit.ly/4p9qspY
🔬 𝙏𝙝𝙚 𝙒𝙖𝙧𝙗𝙪𝙧𝙜 𝙀𝙛𝙛𝙚𝙘𝙩 - bit.ly/4rb6eOs
💡 𝗢𝗽𝗲𝗻 𝗳𝗼𝗿 𝗦𝘂𝗯𝗺𝗶𝘀𝘀𝗶𝗼𝗻𝘀:
🌱 𝙃𝙚𝙧𝙞𝙩𝙖𝙗𝙡𝙚 𝙀𝙣𝙙𝙤𝙘𝙧𝙞𝙣𝙚 𝘾𝙖𝙣𝙘𝙚𝙧𝙨 - bit.ly/43A22O7
🧠 𝙋𝙞𝙩𝙪𝙞𝙩𝙖𝙧𝙮 𝙏𝙪𝙢𝙤𝙪𝙧𝙨 - bit.ly/4p9qTk6
November 18, 2025 at 9:27 AM
Spotlighting our latest completed collections & our open collections for submissions.
✅ 𝗖𝗼𝗺𝗽𝗹𝗲𝘁𝗲𝗱 𝗖𝗼𝗹𝗹𝗲𝗰𝘁𝗶𝗼𝗻𝘀:
🔎 𝙍𝙀𝙏@𝙏𝙝𝙞𝙧𝙩𝙮 - bit.ly/4p9qspY
🔬 𝙏𝙝𝙚 𝙒𝙖𝙧𝙗𝙪𝙧𝙜 𝙀𝙛𝙛𝙚𝙘𝙩 - bit.ly/4rb6eOs
💡 𝗢𝗽𝗲𝗻 𝗳𝗼𝗿 𝗦𝘂𝗯𝗺𝗶𝘀𝘀𝗶𝗼𝗻𝘀:
🌱 𝙃𝙚𝙧𝙞𝙩𝙖𝙗𝙡𝙚 𝙀𝙣𝙙𝙤𝙘𝙧𝙞𝙣𝙚 𝘾𝙖𝙣𝙘𝙚𝙧𝙨 - bit.ly/43A22O7
🧠 𝙋𝙞𝙩𝙪𝙞𝙩𝙖𝙧𝙮 𝙏𝙪𝙢𝙤𝙪𝙧𝙨 - bit.ly/4p9qTk6
✅ 𝗖𝗼𝗺𝗽𝗹𝗲𝘁𝗲𝗱 𝗖𝗼𝗹𝗹𝗲𝗰𝘁𝗶𝗼𝗻𝘀:
🔎 𝙍𝙀𝙏@𝙏𝙝𝙞𝙧𝙩𝙮 - bit.ly/4p9qspY
🔬 𝙏𝙝𝙚 𝙒𝙖𝙧𝙗𝙪𝙧𝙜 𝙀𝙛𝙛𝙚𝙘𝙩 - bit.ly/4rb6eOs
💡 𝗢𝗽𝗲𝗻 𝗳𝗼𝗿 𝗦𝘂𝗯𝗺𝗶𝘀𝘀𝗶𝗼𝗻𝘀:
🌱 𝙃𝙚𝙧𝙞𝙩𝙖𝙗𝙡𝙚 𝙀𝙣𝙙𝙤𝙘𝙧𝙞𝙣𝙚 𝘾𝙖𝙣𝙘𝙚𝙧𝙨 - bit.ly/43A22O7
🧠 𝙋𝙞𝙩𝙪𝙞𝙩𝙖𝙧𝙮 𝙏𝙪𝙢𝙤𝙪𝙧𝙨 - bit.ly/4p9qTk6
Please join us in welcoming Dr. Crona to the Endocrine-Related Cancer community.
Dr. Crona is Associate Professor at Uppsala University, Sweden, and a clinical oncologist with a special interest in endocrine neoplasia.🚀
Dr. Crona is Associate Professor at Uppsala University, Sweden, and a clinical oncologist with a special interest in endocrine neoplasia.🚀
November 13, 2025 at 12:54 PM
Please join us in welcoming Dr. Crona to the Endocrine-Related Cancer community.
Dr. Crona is Associate Professor at Uppsala University, Sweden, and a clinical oncologist with a special interest in endocrine neoplasia.🚀
Dr. Crona is Associate Professor at Uppsala University, Sweden, and a clinical oncologist with a special interest in endocrine neoplasia.🚀
🏆 As we approach the end of 2025, we’re launching the Endocrine-Related Cancer Best Paper Award - celebrating the most outstanding articles published in 2025.
Papers will be selected by our editorial leadership, with 1st place awarded £1000 💜 Stay tuned, selection will take place in 2026!
Papers will be selected by our editorial leadership, with 1st place awarded £1000 💜 Stay tuned, selection will take place in 2026!
November 11, 2025 at 12:20 PM
🏆 As we approach the end of 2025, we’re launching the Endocrine-Related Cancer Best Paper Award - celebrating the most outstanding articles published in 2025.
Papers will be selected by our editorial leadership, with 1st place awarded £1000 💜 Stay tuned, selection will take place in 2026!
Papers will be selected by our editorial leadership, with 1st place awarded £1000 💜 Stay tuned, selection will take place in 2026!
Today, we stand with the global community in recognising everyone affected by neuroendocrine cancer.
At Endocrine-Related Cancer, we remain committed to publishing high-quality research that advances understanding of NETs to optimise patient care.
🔗 lnkd.in/eBY6uA_r
#WorldNeuroendocrineCancerDay
At Endocrine-Related Cancer, we remain committed to publishing high-quality research that advances understanding of NETs to optimise patient care.
🔗 lnkd.in/eBY6uA_r
#WorldNeuroendocrineCancerDay
November 10, 2025 at 12:49 PM
Today, we stand with the global community in recognising everyone affected by neuroendocrine cancer.
At Endocrine-Related Cancer, we remain committed to publishing high-quality research that advances understanding of NETs to optimise patient care.
🔗 lnkd.in/eBY6uA_r
#WorldNeuroendocrineCancerDay
At Endocrine-Related Cancer, we remain committed to publishing high-quality research that advances understanding of NETs to optimise patient care.
🔗 lnkd.in/eBY6uA_r
#WorldNeuroendocrineCancerDay
We’re excited to announce a new Special Collection featuring the most significant clinical & scientific presentations from the 7th International Symposium on Pheochromocytoma.
🔗 For more info: lnkd.in/d3gyVVbg
Collection Editors: Prof. Isabelle Bourdeau, Prof. Karel Pacak
& Prof. André Lacroix
🔗 For more info: lnkd.in/d3gyVVbg
Collection Editors: Prof. Isabelle Bourdeau, Prof. Karel Pacak
& Prof. André Lacroix
November 5, 2025 at 8:18 AM
We’re excited to announce a new Special Collection featuring the most significant clinical & scientific presentations from the 7th International Symposium on Pheochromocytoma.
🔗 For more info: lnkd.in/d3gyVVbg
Collection Editors: Prof. Isabelle Bourdeau, Prof. Karel Pacak
& Prof. André Lacroix
🔗 For more info: lnkd.in/d3gyVVbg
Collection Editors: Prof. Isabelle Bourdeau, Prof. Karel Pacak
& Prof. André Lacroix
Reposted by Endocrine-Related Cancer
🎉 Excited to share our new publication!
Targeted inhibition of netrin–DCC axis with NP137 reverses netrin-driven survival in vitro & reduces high-grade pancreatic NEN progression in vivo.
Potential therapeutic strategy for aggressive PNENs?
bit.ly/435pKBx
@endocancer.bsky.social
Targeted inhibition of netrin–DCC axis with NP137 reverses netrin-driven survival in vitro & reduces high-grade pancreatic NEN progression in vivo.
Potential therapeutic strategy for aggressive PNENs?
bit.ly/435pKBx
@endocancer.bsky.social
November 1, 2025 at 4:03 PM
🎉 Excited to share our new publication!
Targeted inhibition of netrin–DCC axis with NP137 reverses netrin-driven survival in vitro & reduces high-grade pancreatic NEN progression in vivo.
Potential therapeutic strategy for aggressive PNENs?
bit.ly/435pKBx
@endocancer.bsky.social
Targeted inhibition of netrin–DCC axis with NP137 reverses netrin-driven survival in vitro & reduces high-grade pancreatic NEN progression in vivo.
Potential therapeutic strategy for aggressive PNENs?
bit.ly/435pKBx
@endocancer.bsky.social
Lenvatinib is preferred over sorafenib as first-line therapy for RR‑DTC due to superior PFS.
Vincenzo Marotta et al. compared both MKIs in a real‑world, treatment‑naïve cohort: lenvatinib showed higher activity, but no OS benefit.
Subscribers can read the article: doi.org/10.1530/ERC-24-0215
Vincenzo Marotta et al. compared both MKIs in a real‑world, treatment‑naïve cohort: lenvatinib showed higher activity, but no OS benefit.
Subscribers can read the article: doi.org/10.1530/ERC-24-0215
October 29, 2025 at 9:31 AM
Lenvatinib is preferred over sorafenib as first-line therapy for RR‑DTC due to superior PFS.
Vincenzo Marotta et al. compared both MKIs in a real‑world, treatment‑naïve cohort: lenvatinib showed higher activity, but no OS benefit.
Subscribers can read the article: doi.org/10.1530/ERC-24-0215
Vincenzo Marotta et al. compared both MKIs in a real‑world, treatment‑naïve cohort: lenvatinib showed higher activity, but no OS benefit.
Subscribers can read the article: doi.org/10.1530/ERC-24-0215
🧬 Results from clinical trial NCT03969121: Neoadjuvant Hormonal Therapy Plus Palbociclib in Operable, Hormone Sensitive and HER2-Negative Primary Breast Cancer.
Now available in Endocrine-Related Cancer #OpenAccess: doi.org/10.1530/ERC-24-0353
Now available in Endocrine-Related Cancer #OpenAccess: doi.org/10.1530/ERC-24-0353
October 21, 2025 at 9:03 AM
🧬 Results from clinical trial NCT03969121: Neoadjuvant Hormonal Therapy Plus Palbociclib in Operable, Hormone Sensitive and HER2-Negative Primary Breast Cancer.
Now available in Endocrine-Related Cancer #OpenAccess: doi.org/10.1530/ERC-24-0353
Now available in Endocrine-Related Cancer #OpenAccess: doi.org/10.1530/ERC-24-0353
Early-Career Editor Opening!
A great opportunity for early-career researchers to build editorial experience, gain mentorship & shape research.
To apply, send your CV and cover letter to erc@bioscientifica.com by 7 Nov 2025.
Questions? Reach out to erc@bioscientifica.com
A great opportunity for early-career researchers to build editorial experience, gain mentorship & shape research.
To apply, send your CV and cover letter to erc@bioscientifica.com by 7 Nov 2025.
Questions? Reach out to erc@bioscientifica.com
October 17, 2025 at 8:58 AM
Early-Career Editor Opening!
A great opportunity for early-career researchers to build editorial experience, gain mentorship & shape research.
To apply, send your CV and cover letter to erc@bioscientifica.com by 7 Nov 2025.
Questions? Reach out to erc@bioscientifica.com
A great opportunity for early-career researchers to build editorial experience, gain mentorship & shape research.
To apply, send your CV and cover letter to erc@bioscientifica.com by 7 Nov 2025.
Questions? Reach out to erc@bioscientifica.com
New research by Di Sun et al. investigates the long-term efficacy of anlotinib in patients with progressive RAIR-DTC and explores the predictive potential of PET/CT parameters.
🔗 Subscribers of Endocrine-Related Cancer can read the full article: doi.org/10.1530/ERC-25-0027
🔗 Subscribers of Endocrine-Related Cancer can read the full article: doi.org/10.1530/ERC-25-0027
September 30, 2025 at 8:24 AM
New research by Di Sun et al. investigates the long-term efficacy of anlotinib in patients with progressive RAIR-DTC and explores the predictive potential of PET/CT parameters.
🔗 Subscribers of Endocrine-Related Cancer can read the full article: doi.org/10.1530/ERC-25-0027
🔗 Subscribers of Endocrine-Related Cancer can read the full article: doi.org/10.1530/ERC-25-0027
New retrospective cohort study by Branislav Klimacek et al. explores the non-operative management of initially asymptomatic patients diagnosed with small intestine neuroendocrine tumors, raising questions about current guidelines.
Read the full study here #OpenAccess: doi.org/10.1530/ERC-25-0205
Read the full study here #OpenAccess: doi.org/10.1530/ERC-25-0205
September 25, 2025 at 9:00 AM
New retrospective cohort study by Branislav Klimacek et al. explores the non-operative management of initially asymptomatic patients diagnosed with small intestine neuroendocrine tumors, raising questions about current guidelines.
Read the full study here #OpenAccess: doi.org/10.1530/ERC-25-0205
Read the full study here #OpenAccess: doi.org/10.1530/ERC-25-0205
Be part of the global #neuroendocrinecancer research conversation in Boston, November 17-19.
The NETRF (@netrf.org) Annual Research Symposium brings together expert researchers to share leading-edge science and learn from each other.
Register now: bit.ly/4nQ9goU
#NETresearch #cancerresearch
The NETRF (@netrf.org) Annual Research Symposium brings together expert researchers to share leading-edge science and learn from each other.
Register now: bit.ly/4nQ9goU
#NETresearch #cancerresearch
September 24, 2025 at 7:39 AM
Be part of the global #neuroendocrinecancer research conversation in Boston, November 17-19.
The NETRF (@netrf.org) Annual Research Symposium brings together expert researchers to share leading-edge science and learn from each other.
Register now: bit.ly/4nQ9goU
#NETresearch #cancerresearch
The NETRF (@netrf.org) Annual Research Symposium brings together expert researchers to share leading-edge science and learn from each other.
Register now: bit.ly/4nQ9goU
#NETresearch #cancerresearch
Reposted by Endocrine-Related Cancer
Neoadjuvant Palbociclib Plus Endocrine Therapy Does Not Improve PEPI Scores in Resectable HR+ Breast Cancer
#BreastCancer #BCSM @endocancer.bsky.social
www.onclive.com/view/neoadju...
#BreastCancer #BCSM @endocancer.bsky.social
www.onclive.com/view/neoadju...
Neoadjuvant Palbociclib Plus Endocrine Therapy Does Not Improve PEPI Scores in Resectable HR+ Breast Cancer | OncLive
Neoadjuvant palbociclib plus endocrine therapy did not improved PEPI scores in operable hormone receptor–positive breast cancer.
www.onclive.com
September 17, 2025 at 12:35 PM
Neoadjuvant Palbociclib Plus Endocrine Therapy Does Not Improve PEPI Scores in Resectable HR+ Breast Cancer
#BreastCancer #BCSM @endocancer.bsky.social
www.onclive.com/view/neoadju...
#BreastCancer #BCSM @endocancer.bsky.social
www.onclive.com/view/neoadju...
Reposted by Endocrine-Related Cancer
Explore the latest in #pheochromocytoma & #paraganglioma research with Endocrine-Related Cancer’s (@endocancer.bsky.social) special collection, featuring recent advances in genetics, metabolomics, nuclear medicine & more.
Explore the collection: erc.bioscientifica.com/page/PPGL
Explore the collection: erc.bioscientifica.com/page/PPGL
September 16, 2025 at 9:27 PM
Explore the latest in #pheochromocytoma & #paraganglioma research with Endocrine-Related Cancer’s (@endocancer.bsky.social) special collection, featuring recent advances in genetics, metabolomics, nuclear medicine & more.
Explore the collection: erc.bioscientifica.com/page/PPGL
Explore the collection: erc.bioscientifica.com/page/PPGL
🔬 Discovery of a novel sodium iodide symporter regulatory pathway in breast cancer cells.
Vikki L Poole et al. opens new therapeutic avenues in #BreastCancer by mapping sodium iodide symporter regulation & pinpointing targets to boost radioiodide avidity.
Read #OpenAccess: doi.org/10.1530/ERC-...
Vikki L Poole et al. opens new therapeutic avenues in #BreastCancer by mapping sodium iodide symporter regulation & pinpointing targets to boost radioiodide avidity.
Read #OpenAccess: doi.org/10.1530/ERC-...
September 16, 2025 at 9:53 AM
🔬 Discovery of a novel sodium iodide symporter regulatory pathway in breast cancer cells.
Vikki L Poole et al. opens new therapeutic avenues in #BreastCancer by mapping sodium iodide symporter regulation & pinpointing targets to boost radioiodide avidity.
Read #OpenAccess: doi.org/10.1530/ERC-...
Vikki L Poole et al. opens new therapeutic avenues in #BreastCancer by mapping sodium iodide symporter regulation & pinpointing targets to boost radioiodide avidity.
Read #OpenAccess: doi.org/10.1530/ERC-...
New research by Exequiel Gonzalo Alonso et al. uncovers a protumor role for HO-1 in thyroid cancer by enhancing proliferation, migration & cell cycle progression. 🔎
🎯Could HO-1 be a therapeutic target?
Subscribers can read the research: doi.org/10.1530/ERC-25-0177
#ThyroidCancer #CancerResearch
🎯Could HO-1 be a therapeutic target?
Subscribers can read the research: doi.org/10.1530/ERC-25-0177
#ThyroidCancer #CancerResearch
September 9, 2025 at 1:44 PM
New research by Exequiel Gonzalo Alonso et al. uncovers a protumor role for HO-1 in thyroid cancer by enhancing proliferation, migration & cell cycle progression. 🔎
🎯Could HO-1 be a therapeutic target?
Subscribers can read the research: doi.org/10.1530/ERC-25-0177
#ThyroidCancer #CancerResearch
🎯Could HO-1 be a therapeutic target?
Subscribers can read the research: doi.org/10.1530/ERC-25-0177
#ThyroidCancer #CancerResearch
🧠Contribute to Endocrine-Related Cancer's new Special Collection on pituitary tumours!
We welcome basic, translational & clinical studies that advance understanding & showcase innovations in the field.
📩Submit your proposal to: erc@bioscientifica.com
🌐More info: bit.ly/4mUXslc
We welcome basic, translational & clinical studies that advance understanding & showcase innovations in the field.
📩Submit your proposal to: erc@bioscientifica.com
🌐More info: bit.ly/4mUXslc
September 5, 2025 at 3:07 PM
🧠Contribute to Endocrine-Related Cancer's new Special Collection on pituitary tumours!
We welcome basic, translational & clinical studies that advance understanding & showcase innovations in the field.
📩Submit your proposal to: erc@bioscientifica.com
🌐More info: bit.ly/4mUXslc
We welcome basic, translational & clinical studies that advance understanding & showcase innovations in the field.
📩Submit your proposal to: erc@bioscientifica.com
🌐More info: bit.ly/4mUXslc
🎯Targeting RET in medullary thyroid cancer has played a key role in therapeutic strategies in the past decade.
A new review by Kate Newbold and Leslie Cheng explores targeted and selective RET therapies, and highlights the challenge of resistance.
🔗 doi.org/10.1530/ERC-24-0291
A new review by Kate Newbold and Leslie Cheng explores targeted and selective RET therapies, and highlights the challenge of resistance.
🔗 doi.org/10.1530/ERC-24-0291
September 3, 2025 at 7:42 AM
🎯Targeting RET in medullary thyroid cancer has played a key role in therapeutic strategies in the past decade.
A new review by Kate Newbold and Leslie Cheng explores targeted and selective RET therapies, and highlights the challenge of resistance.
🔗 doi.org/10.1530/ERC-24-0291
A new review by Kate Newbold and Leslie Cheng explores targeted and selective RET therapies, and highlights the challenge of resistance.
🔗 doi.org/10.1530/ERC-24-0291